louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02120664: Florbetapir Calibration to the Centiloid Scale
Official title: A Multicenter, Multicountry Study to Calibrate Florbetapir (18F) PET Imaging Data to the Centiloid Scale Based on 11C-PiB
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Alzheimer's Disease
Lead sponsor: Avid Radiopharmaceuticals
Sponsor class: INDUSTRY
First posted: 2014-04-23
Enrollment: 35
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: This study is designed to demonstrate the conversion of florbetapir (18F) Positron Emission Tomography (PET) Standard Uptake Value ratio (SUVr) to Centiloid units.


Eligibility criteria: Inclusion Criteria:

* Cognitively Normal Subjects

  * Males or females ≥ 21 and ≤ 45 years of age
  * Mini-mental state examination (MMSE) ≥ 29
* Clinically Diagnosed AD Subject

  * Males or females ≥ 50 years of age
  * Meet clinical criteria for dementia due to probable AD
  * MMSE ≥ 16 and ≤ 26
* Possible AD Subject

  * Males or females ≥ 50 years of age
  * Meet clinical criteria for dementia due to possible AD
  * MMSE ≥ 16 and ≤ 26
* MCI Subject

  * Males or females ≥ 60 years of age with cognitive impairment (not dementia)
  * MMSE \>24 and \<29
* At Risk Elderly Subject

  * Cognitively normal males or females that are known ApoE4 carriers and ≥ 75 years of age
  * MMSE ≥ 27

Exclusion Criteria:

* Have had or currently have a diagnosis of neurodegenerative disorders other than AD
* Have a current serious or unstable illness that could interfere with completion of the study
* Subject has a known brain lesion, pathology or traumatic brain injury
* Have received or participated in a trial with investigational medications in the past 30 days
* Have had a radiopharmaceutical imaging or treatment procedure within 7 days of study imaging session
* Females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception

Primary outcomes:
measure: Florbetapir SUVr Conversion to Centiloid Units
timeFrame: up to 70 minutes post injection
Secondary outcomes:
measure: Correlation of Florbetapir (18F) Centiloid and 11C-PiB Centiloid
timeFrame: up to 70 minutes post injection
measure: Variability of PET Images in Young Healthy Control Subjects.
timeFrame: up to 70 minutes post injection
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: Research Site
state: Pennsylvania
city: Heidelberg
country: Australia
facility: Research Site
state: Victoria
Study officials:
affiliation: Avid Radiopharmaceuticals, Inc.
name: Chief Medical Officer
role: STUDY_CHAIR
References:
citation: Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, Johnson KA, Mathis CA, Minhas D, Pontecorvo MJ, Rowe CC, Skovronsky DM, Mintun MA. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015 Jan;11(1):1-15.e1-4. doi: 10.1016/j.jalz.2014.07.003. Epub 2014 Oct 28.
Clinical trial NCT01930864: Metformin Plus Irinotecan for Refractory Colorectal Cancer
Official title: Phase II Trial of Metformin Combined to Irinotecan for Refractory Metastatic or Recurrent Colorectal Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Colorectal Neoplasms
Adenocarcinoma
Keywords: metformin
colorectal cancer
chemotherapy
Lead sponsor: Barretos Cancer Hospital
Sponsor class: OTHER
Collaborators: name: University of Campinas, Brazil
name: AC Camargo Cancer Center
First posted: 2013-08-29
Enrollment: 41
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: MetIri seeks to identify if metformin combined to irinotecan can improve tumor control.

Detailed description: MetIri is a two-stage single arm Phase II assessing the role of combination of metformin to irinotecan for colorectal cancer patients already treat with oxaliplatin, fluoropyrimidine, irinotecan and an anti-EGFr antibody if KRAS wild-type.

Eligibility criteria: Inclusion Criteria:

* 18 years or older
* Biopsy-proven colorectal adenocarcinoma
* Ineligibility for curative intent therapy, e.g., surgery or radiation
* Disease progression after oxaliplatin (either adjuvant or palliative), fluoropyrimidine (either adjuvant or palliative), irinotecan, and if Kras wild type a anti-EGFR therapy
* Assessable disease according to RECIST v1.1

Exclusion Criteria:

* known hypersensitivity to metformin or irinotecan
* Uncontrolled Central nervous system metastasis
* Acute or chronic severe infection

Primary outcomes:
measure: Non-Progression at week 12th of treatment
timeFrame: 12th week
Secondary outcomes:
measure: Progression-free survival
timeFrame: 12th week
measure: Overall Survival
timeFrame: 12th week
measure: Quality of life
timeFrame: 12th week
measure: Safety
timeFrame: 12th week
Other outcomes:
Locations:
city: Barretos
country: Brazil
facility: Barretos Cancer Hospital
state: SP
city: Campinas
country: Brazil
facility: State University of Campinas
state: São Paulo
Study officials:
affiliation: AC Camargo Cancer Center
name: Joao Paulo SN Lima, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Rocha GZ, Dias MM, Ropelle ER, Osorio-Costa F, Rossato FA, Vercesi AE, Saad MJ, Carvalheira JB. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin Cancer Res. 2011 Jun 15;17(12):3993-4005. doi: 10.1158/1078-0432.CCR-10-2243. Epub 2011 May 4.
Clinical trial NCT02885064: Shifts in the Oral Biofilm of Patients With Known Oral Health Risk Factors
Official title: Shifts in the Oral Biofilm of Patients With Known Oral Health Risk Factors
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Dental Caries
Gingivitis
Lead sponsor: University of North Carolina, Chapel Hill
Sponsor class: OTHER
First posted: 2016-08-31
Enrollment: 34
Sex: ALL
Minimum age (years): 8
Maximum age (years): 99
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients entering and then undergoing orthodontic treatment

Brief summary: This study is observational only and is intended to evaluate changes in the makeup and function of bacteria naturally present in the mouth during treatment with braces to straighten teeth.


Eligibility criteria: Inclusion Criteria:

* ASA I or II (ASA I is a healthy patient, ASA II is patient with minor systemic disease)
* Patient must be receiving orthodontic treatment at the University of North Carolina School of Dentistry and not yet be in active treatment

Exclusion Criteria:

* Patients who have used antibacterial therapy in the past 3 months
* Patients who report current smoking
* ASA III or above (Patients with severe systemic diseases)

Primary outcomes:
measure: Change in Shannon diversity index from Baseline to Month 6
timeFrame: Baseline, Month 6
measure: Change from Baseline to Month 6 in Clusters Of Orthologous Groups of proteins
timeFrame: Baseline, Month 6
Secondary outcomes:
measure: Change in gingival index
timeFrame: Baseline, Month 6
measure: Change in decalcification index
timeFrame: Baseline, Month 6
Other outcomes:
Locations:
city: Chapel Hill
country: United States
facility: UNC School of Dentistry
state: North Carolina
Study officials:
affiliation: University of North Carolina, Chapel Hill
name: Laura Jacox, DMD, PhD, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06155864: Imaging Study of Anatomical Variations of the Superficial Temporal Artery (EVATSI)
Official title: Imaging Study of Anatomical Variations of the Superficial Temporal Artery
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Superficial Temporal Artery
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
First posted: 2023-12-05
Enrollment: 700
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who underwent "Polygon of Willis" imaging of the arteries of the head in the medical imaging department of Brest University Hospital.

Brief summary: This study focuses on the anatomy of the superficial temporal artery, an artery of the head. Knowledge of the anatomy of this artery, and the evaluation of methods for exploring it, have implications for clinical medical and surgical practice.

Detailed description: The study will be divided into several parts:

* The aim is to study the reproducibility of anatomical measurements of the superficial temporal artery using CTA.
* The aim is to study the contribution of CTA for the anatomical assessment of the superficial temporal artery.
* The aim is to evaluate the performance of MRI in the anatomical study of the superficial temporal artery.

Eligibility criteria: Inclusion Criteria:

* No opposition expressed
* Examination analyzable

Exclusion Criteria:

* Refusal to participate

Primary outcomes:
measure: Intra- and inter-observer reproducibility of anatomical criteria of the superficial temporal artery in CTA.
timeFrame: 12 months
measure: Evaluation of anatomical measurements and reproducibility of measurements obtained with an iterative and classical reconstruction CT technique.
timeFrame: 12 months
measure: Study the anatomy of the superficial temporal artery in a large number of patients, and to correlate the anatomical variants observed with the age of the subjects.
timeFrame: 12 months
measure: The aim is to compare the performance of arterial time-of-flight (TOF) sequences in MRI at 1.5T and 3T with angio-CT. A comparative analysis of the anatomical measurements obtained with each technique will be carried out.
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Brest
country: France
facility: Chu Brest
city: Brest
country: France
facility: Chu Brest
Study officials:
References:
Clinical trial NCT02253290: Neuropsychological and Psychosocial Follow up of Children and Adolescents With Neuromuscular Disease
Official title: Neuropsychological and Psychosocial Follow up of Children and Adolescents With Neuromuscular Disease
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Neuromuscular Diseases
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor class: OTHER
First posted: 2014-10-01
Enrollment: 300
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: children and adolescents with neuromuscular disease

Brief summary: This project is a retrospective and prospective investigation of neuropsychological and psychosocial development of children with a neuromuscular disease.

Detailed description: This project is a retrospective and prospective investigation of neuropsychological and psychosocial development of children with a neuromuscular disease. Children and adolescents in UZ Leuven will be evaluated according to a psychosocial and neuropsychological protocol including different psychological tests and patient questionaires.

Eligibility criteria: Inclusion criteria

* children and adolescents (0-18 years)
* diagnosis of neuromuscular disease

Primary outcomes:
measure: Neuropsychological profile (questionnaires, neuropsychological testing) of children with myotonic dystonia type 1
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: UZ Leuven
Study officials:
affiliation: UZ Leuven
name: Nathalie Goemans, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: UZ Leuven
name: Liesbeth De Waele, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00728390: A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks
Official title: Phase 1 Targeted Combination Trial Of PF-00299804 And CP-751,871 In Patients With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Carcinoma, Non-Small Cell
Neoplasm Metastasis
Keywords: advanced cancer refractory advanced non-small cell lung cancer
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2008-08-05
Enrollment: 74
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will explore the combination of the oral drug PF-00299804 and intravenous CP-751,871 in patients with advanced solid tumor. Each of these drugs have been given separately to patients in prior studies, and this study is to establish the safety and efficacy of the combination.


Eligibility criteria: Inclusion Criteria:

* Histologically documented advanced cancer, Eastern Cooperative Oncology Group (ECOG) 0-1;
* Platelets \> 100,000, ANC \> 1500;
* Ccr \> 60 or serum creat. \<1.5
* Non-small cell cancer cohort:
* Eastern Cooperative Oncology Group (ECOG) 0-2, prior platin, \< 4 prior chemotherapy regimen
* HgA1C \<5.7%

Exclusion Criteria:

* Active Central Nervous System (CNS) metastases;
* prior IGF1-R targeted therapy
* Any history of unstable angina, myocardial infarction or symptomatic congestive heart failure.

Primary outcomes:
measure: Overall safety profile characterized by type, frequency, severity (as graded using NCI CTC AE v. 3.0), timing, seriousness and relationship to trial treatment of adverse events and laboratory abnormalities.
timeFrame: 18 months
Secondary outcomes:
measure: Plasma Pharmacokinetic Parameters of PF-00299804 and CP-751,871
timeFrame: 12 months
measure: Progression Free Survival (PFS)
timeFrame: 15 months
measure: Best overall response (OR) defined according to RECIST guidelines.
timeFrame: 12 months
measure: Duration of response (DR)
timeFrame: 15 months
measure: Anti-Drug Antibodies (ADA) response;
timeFrame: 18 months
measure: KRAS mutation and EGFR gene amplification and mutation status in available NSCLC tumor tissue (fresh or archived) (NSCLC MTD Expansion Cohort
timeFrame: 12 months
Other outcomes:
Locations:
city: Amherst
country: United States
facility: Pfizer Investigational Site
state: New York
city: Buffalo
country: United States
facility: Pfizer Investigational Site
state: New York
city: San Antonio
country: United States
facility: Pfizer Investigational Site
state: Texas
city: Villejuif
country: France
facility: Pfizer Investigational Site
city: Madrid
country: Spain
facility: Pfizer Investigational Site
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT00442390: Metabolic Effects of Acute Cortisol Withdrawal in Adrenal Failure
Official title: Effects of Cortisol on Carbohydrate, Lipid, and Protein Metabolism; Studies of Acute Cortisol Withdrawal in Adrenocortical Failure.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Addison Syndrome
Keywords: Cortisol
adrenal insufficiency
glucose metabolism
protein metabolism
lipid metabolism
insulin sensitivity.
Lead sponsor: University of Aarhus
Sponsor class: OTHER
First posted: 2007-03-01
Enrollment: 10
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Effects of adrenal steroids is generelly drawn from studies of hypercortisolism. The effects of physiological cortisol substitution and withdrawal is studied and related to the clinical syndrome of adrenal insufficiency.


Eligibility criteria: Inclusion Criteria:

* Female adrenal failure
* Age 18-50
* Written informed content

Exclusion Criteria:

* Diabetes mellitus
* Cancer
* Thromboembolic events
* Pregnancy and lactation
* Heart disease

Primary outcomes:
measure: insulin sensitivity
measure: local protein turnover
measure: whole body protein turnover
measure: glucose metabolism
measure: serum metabolites
measure: serum hormone levels
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Aarhus
name: Jens Juel Christiansen, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Aarhus
name: Claus H Gravholt, MD
role: STUDY_CHAIR
affiliation: University of Aarhus
name: Christian B Djurhuus, PhD
role: STUDY_CHAIR
affiliation: University of Aarhus
name: Per Iversen, PhD
role: STUDY_CHAIR
affiliation: University of Aarhus
name: Jens S Christiansen, Professor
role: STUDY_CHAIR
affiliation: University of Aarhus
name: Ole Schmidt, Professor
role: STUDY_CHAIR
affiliation: University of Aarhus
name: Jørgen Weeke, Professor
role: STUDY_CHAIR
affiliation: University of Aarhus
name: Jens OL Jørgensen, MD
role: STUDY_CHAIR
affiliation: University of Aarhus
name: Niels Møller, Professor
role: STUDY_DIRECTOR
References:
Clinical trial NCT03587090: Comparison of Subcostal and Transhepatic Views to Assess Inferior Vena Cava by Echocardiography
Official title: Comparaison échographique Des Voies Sous Costale et Trans hépatique Dans l'évaluation de la Veine Cave inférieure
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Inferior Vena Cava Diameter
Lead sponsor: University Hospital, Caen
Sponsor class: OTHER
First posted: 2018-07-16
Enrollment: 131
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: intensive care unit patients

Brief summary: Comparison of subcostal and transhepatic views to measure inferior vena cava diameter by echocardiography in intensive care unit patients


Eligibility criteria: Inclusion Criteria:

* patient hospitalised in ICU

Exclusion Criteria:

* gardianship
* contraindication to transthoracic echocardiography

Primary outcomes:
measure: inferior vena cava diameter
timeFrame: up to 1 day after inclusion
Secondary outcomes:
Other outcomes:
Locations:
city: Caen
country: France
facility: Service de réanimation médicale CHU de Caen
Study officials:
References:
Clinical trial NCT00373490: A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048)
Official title: MK0683 Phase1 Clinical Study - Solid Tumor -
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Tumors
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2006-09-08
Enrollment: 16
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a clinical study to evaluate the safety and pharmacokinetics of an overseas determined maximum tolerated dose (MTD) of MK-0683 (vorinostat) in a Japanese patient population with solid tumors.


Eligibility criteria: Inclusion Criteria:

* Patients with histologically or cytologically diagnosed solid tumor in whom no standard therapy is available or the malignancy is refractory to standard therapy

Exclusion Criteria:

* Patients with history of immunotherapy, radiotherapy, surgery, or chemotherapy during the previous 4 weeks
* Any uncontrolled concomitant illness
* Pregnant or breast-feeding
* Serious drug or food allergy

Primary outcomes:
measure: Number of Participants With a Dose Limiting Toxicity (DLT)
timeFrame: 21 Days (first cycle)
Secondary outcomes:
measure: Area Under the Curve (AUC(0-infinity)) at Day 1 (600 mg and 400 mg)
timeFrame: Day 1 (600 mg and 400 mg)
measure: Area Under the Curve (AUC(0-infinity)) at Day 3 (600 mg)
timeFrame: Day 3 (600 mg)
measure: Area Under the Curve (AUC(0-infinity) at Day 21 (400 mg)
timeFrame: Day 21 (400 mg)
measure: Maximum Concentration (Cmax) at Day 1 (600 mg and 400 mg)
timeFrame: Day 1 (600 mg and 400 mg)
measure: Maximum Concentration (Cmax) at Day 3 (600 mg)
timeFrame: Day 3 (600 mg)
measure: Maximum Concentration (Cmax) at Day 21 (400 mg)
timeFrame: Day 21 (400 mg)
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Director
role: STUDY_DIRECTOR
References:
citation: Doi T, Hamaguchi T, Shirao K, Chin K, Hatake K, Noguchi K, Otsuki T, Mehta A, Ohtsu A. Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial. Int J Clin Oncol. 2013 Feb;18(1):87-95. doi: 10.1007/s10147-011-0348-6. Epub 2012 Jan 11.
Clinical trial NCT01295190: Substitution of Propofol by Sevoflurane During Pediatric Cardiopulmonary Bypass
Official title: Substitution of Propofol by Sevoflurane During Pediatric Cardiopulmonary Bypass: Effect on Metabolic Acidosis and Clinical Outcome
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Metabolic Acidosis
Lead sponsor: University Hospital Schleswig-Holstein
Sponsor class: OTHER
First posted: 2011-02-14
Enrollment: 200
Sex: ALL
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children scheduled for heart surgery including cardiopulmonary bypass.

Brief summary: Propofol has been routinely used for general anesthesia during pediatric cardiopulmonary bypass at our institution without complications. However, propofol may cause propofol infusion syndrome (PRIS), a rare, but often fatal complication mainly defined by bradycardia with progress to asystolia. Metabolic acidosis is regarded as an early warning sign of PRIS. Due to the preconditioning effects of sevoflurane and its availability for cardiopulmonary bypass, propofol has recently been substituted by sevoflurane during pediatric cardiopulmonary bypass at our institution. In this study the effect of substituting propofol by sevoflurane on metabolic acidosis and outcome are examined.

Detailed description: In this retrospective and partially prospective observational study the charts of 200 children anesthetised for pediatric heart surgery are analysed since September 2007. 100 children received propofol and up to now 80 children received sevoflurane during cardiopulmonary bypass. Blood gas analysis, laboratory results and vital parameters are compared before and after cardiopulmonary bypass for each group. Duration of intensive care treatment and time to dismission from hospital are compared between groups. Changes relative to baseline are analysed by paired t-Test with correction for multiple testing. Differences between groups are analysed by unpaired t-Test with correction for multiple testing

Eligibility criteria: Inclusion Criteria:

* Children scheduled for heart surgery including cardiopulmonary bypass

Primary outcomes:
measure: Metabolic acidosis during cardiopulmonary bypass
timeFrame: 2 hours
Secondary outcomes:
measure: Outcome parameter
timeFrame: 1 month
Other outcomes:
Locations:
city: Kiel
country: Germany
facility: University Hospital Schleswig-Holstein
state: Schleswig-Holstein
Study officials:
affiliation: University Hospital Schleswig-Holstein
name: Axel Fudickar, Dr.
role: PRINCIPAL_INVESTIGATOR
References: